Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10110719 | 0.89 | TAAR1 (0.50) | ALDH1A1TAAR1FFAR1MAOBDAO | |
| SCHEMBL18768957 | 0.86 | ALDH1A1 (0.72) | ALDH1A1FFAR1MAOAKDM4ENPC1 | |
| SCHEMBL7340106 | 0.85 | TAAR1 (0.57) | TAAR1FFAR1CASP3CASP7DAO | |
| SCHEMBL7955428 | 0.85 | TAAR1 (0.57) | TAAR1FFAR1MAOBCASP3CASP7 | |
| SCHEMBL334758 | 0.83 | FFAR1 (0.68) | TAAR1FFAR1CASP3CASP7 | |
| SCHEMBL9626407 | 0.82 | MAOB (0.69) | FFAR1MAOBMAOA | |
| SCHEMBL23901663 | 0.82 | IAPP (0.56) | TAAR1FFAR1MAOBCASP3CASP7 | |
| SCHEMBL1447034 | 0.81 | TAAR1 (0.53) | TAAR1FFAR1CASP3CASP7DAO | |
| SCHEMBL2857831 | 0.81 | TAAR1 (0.58) | TAAR1FFAR1MAOBCASP3CASP7 | |
| SCHEMBL30344632 | 0.81 | TAAR1 (0.58) | TAAR1FFAR1MAOBCASP3CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024050825-A1 | COMPOUNDS AS MLKL INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2024-03-14 | — | — | WO | disclosed |
| US-20230303493-A1 | ANTIBACTERIAL ADJUVANTS AND APPLICATIONS THEREOF | SAN JOSE STATE UNIVERSITY RESEARCH FOUNDATION | 2023-09-28 | — | — | US | disclosed |
| EP-2970235-B1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2019-06-19 | — | — | EP | disclosed |
| EP-3103797-B1 | 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS | ALLERGAN INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9868717-B2 | Tricyclic sulphonamide compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ZAFGEN, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9624182-B2 | Compounds as lysophosphatidic acid receptor antagonists | AMIRA PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9617237-B2 | Partially saturated tricyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2483252-B1 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| WO-1998056752-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1998-12-17 | — | — | WO | disclosed |
| EP-0831799-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1997046511-A1 | COUMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1997-12-11 | — | — | WO | disclosed |
| WO-1996040097-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0743853-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1995021612-A2 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMACEUTICALS, INC. (US) | 1995-08-17 | — | — | WO | disclosed |
| US-4487969-A | DIAZOTIZATION OF M-AMINOACETOPHENONE FOLLOWED BY HEAT DECOMPOSITION | OLIN CORPORATION (US) | 1984-12-11 | — | — | US | disclosed |
| EP-0105641-A1 | Production of m-fluoroacetophenone | OLIN CORPORATION (US) | 1984-04-18 | — | — | EP | disclosed |
| US-4160036-A | ADRENERGIC STIMULANTS | ALLEN & HANBURYS LIMITED (GB) | 1979-07-03 | — | — | US | disclosed |
| US-4140713-A | Phenylethanolamine therapeutic agents | ALLEN & HANBURYS LIMITED (GB) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326099-A1 | METHODS OF TREATING LIVER DISEASES | ENPEP, GOT2, METAP2 | ALDH1A1 312/4885TAAR1 1374/4885FFAR1 1354/4885 |
| US-20230303493-A1 | ANTIBACTERIAL ADJUVANTS AND APPLICATIONS THEREOF | CAPG, SLC11A2, CAPRIN1 | ALDH1A1 4657/4885TAAR1 4154/4885FFAR1 2959/4885 |
| US-20180002307-A1 | PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, CES2, AADAC | ALDH1A1 1755/4885TAAR1 1443/4885FFAR1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.